Results 41 to 50 of about 8,366 (155)

OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs

mSphere, 2019
Infections due to carbapenemase-producing Gram-negative pathogens are associated with limited treatment options and consequently lead to increased mortality and morbidity.
Christopher Fröhlich, Vidar Sørum, Ane Molden Thomassen, Pål Jarle Johnsen, Hanna-Kirsti S. Leiros, Ørjan Samuelsen   +5 more
doaj   +1 more source

German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant Pseudomonas aeruginosa Isolates Using a Commercially Available Broth Microdilution Assay

Antibiotics, 2022
Multidrug resistance is an emerging healthcare issue, especially concerning Pseudomonas aeruginosa. In this multicenter study, P. aeruginosa isolates with resistance against meropenem detected by routine methods were collected and tested for ...
Jana Manzke, Raphael Stauf, Bernd Neumann, Ernst Molitor, Gunnar Hischebeth, Michaela Simon, Jonathan Jantsch, Jürgen Rödel, Sören L. Becker, Alexander Halfmann, Thomas A. Wichelhaus, Michael Hogardt, Annerose Serr, Christina Hess, Andreas F. Wendel, Ekkehard Siegel, Holger Rohde, Stefan Zimmermann, Jörg Steinmann   +18 more
doaj   +1 more source

Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance [PDF]

Antimicrobial Agents and Chemotherapy, 2018
We tested ceftazidime-avibactam and colistin against 24 carbapenem-resistant Enterobacteriaceae (CRE) isolates by time-kill studies. Ceftazidime-avibactam at 0.25×, 1×, and 4× the MIC was bactericidal against 8%, 21%, and 88% of the isolates, respectively.
Ryan K, Shields, M Hong, Nguyen, Binghua, Hao, Ellen G, Kline, Cornelius J, Clancy   +4 more
openaire   +2 more sources

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis

Access Microbiology, 2020
Pseudomonas aeruginosa is an important bacterial cause of a variety of infections and is associated with high morbidity and mortality. Infections caused by this bacterium are becoming more difficult to treat due to increasing resistance to many of the available antibiotics. Ceftolozane–tazobactam and ceftazidime–avibactam are two new
Jeremy Jacobs, Alexander Maris, Charles Stratton   +2 more
openaire   +2 more sources

Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae

Antibiotics, 2022
Background: Carbapenemase-producing Klebsiella pneumoniae and Escherichia coli have become a significant global health challenge. This has created an urgent need for new treatment modalities.
Karoline Knudsen List, Mette Kolpen, Kasper Nørskov Kragh, Godefroid Charbon, Stine Radmer, Frank Hansen, Anders Løbner-Olesen, Niels Frimodt-Møller, Frederik Boetius Hertz   +8 more
doaj   +1 more source

Case Report: Pharmacokinetics of ceftazidime and avibactam during and after CRRT in an elderly patient and their associations with CNS adverse effects

Frontiers in Pharmacology
Ceftazidime/avibactam is effective for treating infections caused by multidrug-resistant gram-negative bacteria and is widely used. The pharmacokinetic data of ceftazidime and avibactam in patients receiving continuous renal replacement therapy (CRRT ...
Haiying Huang, Yun Han, Yinshan Wu, Feng Guo, Zhenwei Yu   +4 more
doaj   +1 more source

In Vitro Activities of Ceftazidime-Avibactam and Comparator Agents Against Carbapenem-resistant Enterobacterales (CRE) Collected in Africa/Middle East ATLAS Global Surveillance Program 2018-2022

International Journal of Infectious Diseases
Introduction: Avibactam (AVI) is a non-β-lactam β-lactamase inhibitor that when combined with the β-lactam ceftazidime (CAZ) has demonstrated activity against Class A, Class C and some Class D enzymes.
Dr Meredith Hackel, Dr Gregory Stone, Dr Daniel Sahm   +2 more
doaj   +1 more source

Antibiotic Susceptibility of Aerobic and Facultative Anaerobic Gram-Negative Rods in Hong Kong and Implications on Usefulness of Ceftazidime-Avibactam and Ceftolozane-Tazobactam

Antibiotics
Due to the increasing resistance of aerobic and facultative anaerobic Gram-negative rods, ceftazidime-avibactam and ceftolozane-tazobactam have been launched in the market in the last few years.
Jade L. L. Teng, Elaine Chan, Tsz Tuen Li, Tsz Ying Kwan, Ka Fai Chan, Wing Ho Li, Viki W. K. Tang, Man Lung Yeung, Susanna K. P. Lau, Patrick C. Y. Woo   +9 more
doaj   +1 more source

Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria

Фармакоэкономика, 2019
Aim: to assess the economic outcomes of using ceftazidime + avibactam (compared with the recommended treatments) in adult patients with sepsis caused by carbapenem-resistant enterobacteria.Methods.
S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova   +3 more
doaj   +1 more source

Ceftazidime-avibactam induced renal disorders: past and present

Frontiers in Pharmacology
With the increasing prevalence of multidrug-resistant Gram-negative bacterial pathogens worldwide, antimicrobial resistance has become a significant public health concern. Ceftazidime-avibactam (CAZ-AVI) exhibited excellent in vitro activity against many carbapenemase-producing pathogens, and was widely used for the treatment of various complicated ...
Yanrong Shi, Jichao Wu, Wei Mi, Xusheng Zhang, Xiuli Ren, Chengwu Shen, Cuicui Lu   +6 more
openaire   +3 more sources